1. |
|
|
2. |
|
|
3. |
|
|
4. |
|
|
5. |
|
|
6. |
|
|
7. |
- Hartvig, P, et al.
(författare)
-
Interaction of a muscarinic cholinergic agonist on acetylcholine and dopamine receptors in the monkey brain studied with positron emission tomography
- 2002
-
Ingår i: Dementia and geriatric cognitive disorders. - : S. Karger AG. - 1420-8008 .- 1421-9824. ; 13:4, s. 199-204
-
Tidskriftsartikel (refereegranskat)abstract
- The effects on the binding to cholinergic and dopaminergic receptors in the brain during continuous intravenous infusion of the muscarinic cholinergic receptor agonist milameline (CI-979) were studied in the rhesus monkey by means of positron emission tomography. Binding to milameline cholinergic receptors was quantified using the muscarinic receptor antagonist [<sup>11</sup>C]-N-methyl-4-piperidinylbenzilate ([<sup>11</sup>C]NMP), and the effects on nicotine receptor binding were measured with <i>(S)</i>-[<sup>11</sup>C-methyl]nicotine. Changes in the binding of the D<sub>2</sub> dopamine receptor antagonist [<sup>11</sup>C]raclopride were measured as well. The binding of [<sup>11</sup>C]NMP increased in most brain regions with the infusion of increasing doses of milameline from 0.5 to 10 µg/kg/h. <i>(S)</i>-[<sup>11</sup>C-methyl]nicotine binding was unchanged or increased somewhat. Binding of [<sup>11</sup>C]raclopride to the D<sub>2</sub> dopaminergic receptors in the striatum of the brain increased by 10 ± 4% following 2 µg/kg/h of milameline. The results suggest a possible action of milameline both on presynaptic muscarinic receptor subtypes as well as dopamine levels dependent on the receptor reserve of the muscarinic receptor subtypes.
|
|
8. |
|
|
9. |
|
|
10. |
|
|